ClinicalTrials.gg
CompletedNCT04677660Updated May 3, 2023Results posted

A Study of TAK-919 in Healthy Japanese Adults (COVID-19)

A Phase 1/2 interventional study of TAK-919 and Placebo in Coronavirus Disease (COVID-19), sponsored by Takeda. Completed at 2 sites in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Takeda · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
27th of 36
200 · median 499
Started
2021
with 20 others
Phase 1/2
3 of 36
none open now
Registered
5th of 36
by date

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 27th largest by enrollment, is one of 21 that started in 2021, is one of 3 in phase 1/2, and was the 5th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

TAK-919 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-919 can protect people from Covid-19 and to check for side effects from TAK-919.

At the first visit, the study doctor will check if each person can take part. Those who can take part will be chosen for 1 of 2 treatments by chance. Participants will either receive an injection of TAK-919 or a placebo in their arm. In this study, a placebo will look like the TAK-919 vaccine but will not have any medicine in it. 3 times as many participants will receive TAK-919 than placebo. Participants will receive 2 injections of TAK-919 or placebo, 28 days apart.

Participants will be asked to record their temperature and any medical problems in an electronic diary for up to 7 days after each injection.

During the study, participants will visit the clinic for regular check-ups, blood tests, and sometimes for nose swab samples. When all participants have visited their clinic 28 days after their 2nd injection, the study sponsor (Takeda) will check how many participants have made enough antibodies to protect them against Covid-19.

The participants will stay in the study for up to 12 months after they have had their 2nd injection. During this time, the study doctors will continue to check how many participants have made enough antibodies to protect them against Covid-19. Also, they will check if participants have any more side effects from TAK-919 or the placebo.

Read the detailed description

The drug being tested in this study is called TAK-919. TAK-919 is being tested to prevent infectious disease caused by Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2). This study will look at the safety and immunogenicity of 2 doses of TAK-919 by intramuscular (IM) injection in healthy Japanese male and female adults, given 28 days apart.

The study will enroll approximately 200 healthy volunteers. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • TAK-919 0.5 mL
  • Placebo- this is an injection that looks like the study drug but has no active ingredient

All participants will be asked to take intramuscular injection in the upper arm twice throughout the study.

This multi-center trial will be conducted in Japan. The overall time to participate in this study is 12 months from the second vaccination. Participants will make multiple visits to the clinic and will be contacted by telephone or a final visit after the last vaccination for a follow-up assessment.

03

Conditions studied

  • Coronavirus Disease (COVID-19)

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Japanese male and female participants.
  2. Participants who understand and are willing to comply with trial procedures and are available for the duration of follow up.

Exclusion criteria

Exclusion Criteria:

  1. Participants who received any other SARS-CoV-2 or other experimental novel coronavirus vaccine prior to the trial.
  2. Participants who have close contact of anyone known to have COVID-19 within 30 days prior to vaccine administration.
  3. Participants who were tested positive for SARS-CoV-2 prior to the trial or on the test before the vaccination.
  4. Participants who are on current treatment with other agents for prophylaxis of COVID 19.
  5. Participants who traveled outside of Japan in the 30 days prior to the trial participation.
  6. Participants with a active infection (as assessed by the Investigator) or oral temperature >= 38 degree Celsius within 3 days of the vaccination.
  7. Participants with a known or allergy to any of the IMP components.
  8. Participants with any illness or history of any illness that, in the opinion of the Investigator, might interfere with the results of the trial or pose additional risk to the participants due to participation in the trial.
  9. Participants with known or suspected impairment/alteration of immune function, including history of any disease or neuro-inflammatory disease.
  10. Abnormalities of splenic or thymic function.
  11. Participants with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
  12. Participants with any serious chronic or progressive disease (eg, neoplasm, insulin dependent diabetes, cardiac, renal, or hepatic disease).
  13. Participants with >= 30 kg/m\^2 (BMI=weight in kg/height in meters\^2).
  14. Participants participating in any clinical trial with another investigational product within 30 days prior to the vaccination or intend to participate in another clinical trial at any time during the conduct of this trial.
  15. Participants who received or plan to receive any other vaccines within 14 days (for inactivated vaccines) or 28 days (for ) prior to trial dose administration.
  16. Participants with acute or chronic clinically significant disease including pulmonary, cardiovascular, hepatic, or renal abnormality evaluated by physical examination.
  17. Participants involved in the trial conduct or their first-degree relatives.
  18. Participants who are with or have history of and infection, or with known (HIV) infection or HIV-related disease..
  19. Female participants who are pregnant or breastfeeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    TAK-919

    TAK-919 0.5 mL, intramuscular injection in the upper arm

    Biological: TAK-919

  • Placebo comparator
    Placebo

    TAK-919 Matching Placebo, intramuscular injection in the upper arm

    Biological: Placebo

Interventions

  • BiologicalTAK-919

    TAK-919 intramuscular injection

  • BiologicalPlacebo

    Placebo intramuscular injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination

    Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited local AEs included injection site pain, erythema/redness, swelling, induration, and axillary (underarm) swelling or tenderness ipsilateral to the side of injection.

    Time frame: Up to Day 7 (6 subsequent days after first vaccination on Day 1)

  2. Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination

    Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited local AEs included injection site pain, erythema/redness, swelling, induration, and axillary (underarm) swelling or tenderness ipsilateral to the side of injection.

    Time frame: Up to Day 35 (6 subsequent days after second vaccination on Day 29)

  3. Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination

    Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited systemic AEs included headache, fatigue, myalgia, arthralgia, nausea/ vomiting, chills, fever.

    Time frame: Up to Day 7 (6 subsequent days after first vaccination on Day 1)

  4. Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination

    Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited systemic AEs included headache, fatigue, myalgia, arthralgia, nausea/ vomiting, chills, fever.

    Time frame: Up to Day 35 (6 subsequent days after second vaccination on Day 29)

  5. Percentage of Participants With Unsolicited AEs for 28 Days Following First Vaccination

    Unsolicited AEs were all AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary.

    Time frame: Up to Day 29 (28 days after first vaccination on Day 1)

  6. Percentage of Participants With Unsolicited AEs for 28 Days Following Second Vaccination

    Unsolicited AEs were all AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary.

    Time frame: Up to Day 57 (28 days after second vaccination on Day 29)

  7. Percentage of Participants With Serious Adverse Events (SAEs) Until Day 57

    Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this outcome measure (OM) and solicited SAE was out of the scope of the assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs until Day 57 was reported in this outcome measure.

    Time frame: Day 1 up to Day 57

  8. Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 57

    MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAEs was out of the scope of the assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs until Day 57 was reported in this outcome measure.

    Time frame: Day 1 up to Day 57

  9. Percentage of Participants With Any AE Leading to Discontinuation of Vaccination

    Only unsolicited AE leading to discontinuation of vaccination data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to discontinuation of vaccination was out of the scope of the assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to discontinuation of vaccination was reported in this outcome measure.

    Time frame: Day 1 up to Day 57

  10. Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 57

    Only unsolicited AE leading to participant's withdrawal data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal was out of the scope of the assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to participant's withdrawal from the trial until Day 57 was reported in this outcome measure.

    Time frame: Day 1 up to Day 57

  11. Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 57

    Time frame: Day 1 up to Day 57

  12. Geometric Mean Titers (GMT) of Serum Binding Antibody (bAb) Against SARS-CoV-2 on Day 57

    GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values measured as below lower limit of quantification (LLOQ) were imputed to a value that is half of the LLOQ. Titer values measured as above upper limit of quantification (ULOQ) were imputed at the ULOQ value. LLOQ=1 and ULOQ= 2052. GMT of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 spike (S) protein.

    Time frame: At Day 57

  13. Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57

    The GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention. GMFR of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

    Time frame: At Day 57

  14. Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57

    SCR was defined as percentage of participants with a change from below limit of detection (LOD) or LLOQ to equal to or above LOD or LLOQ, OR, greater than or equal to (\>=) 4-fold rises from baseline. LLOQ= 1, ULOQ= 2052. Baseline was defined as the last measurement taken before the first dose of study intervention. SCR of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

    Time frame: At Day 57

Secondary outcomes

  1. Percentage of Participants With SAE Throughout the Trial

    Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this OM and solicited SAE was out of the scope of the assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs throughout the trial was reported in this outcome measure.

    Time frame: Day 1 up to Day 394

  2. Percentage of Participants With MAAEs Throughout the Trial

    MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAEs was out of the scope of the assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs throughout the trial was reported in this outcome measure.

    Time frame: Day 1 up to Day 394

  3. Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial

    Only unsolicited AE leading to participant's withdrawal data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal was out of the scope of the assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to participant's withdrawal from the trial from the day of vaccination throughout the trial was reported in this outcome measure.

    Time frame: Day 1 up to Day 394

  4. Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial

    Time frame: Day 1 up to Day 394

  5. GMT of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394

    GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values measured as below LLOQ were imputed to a value that is half of the LLOQ. Titer values measured as above ULOQ were imputed at the ULOQ value. LLOQ=1 and ULOQ= 2052 until Day 43; LLOQ= 1 and ULOQ= 20520 from Day 209 and later. GMT of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

    Time frame: At Days 29, 43, 209 and 394

  6. GMFR of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394

    The GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention. GMFR of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

    Time frame: At Days 29, 43, 209 and 394

  7. SCR of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394

    SCR was defined as percentage of participants with a change from below LOD or LLOQ to equal to or above LOD or LLOQ, OR \>=4-fold rises from baseline. LLOQ= 1 and ULOQ= 2052 until Day 43; LLOQ= 1 and ULOQ= 20520 from Day 209 and later. Baseline was defined as the last measurement taken before the first dose of study intervention. SCR of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

    Time frame: At Days 29, 43, 209 and 394

  8. GMT of Serum Neutralizing Antibody (nAb) Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394

    GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values measured as below LLOQ were imputed to a value that is half of the LLOQ. Titer values measured as above ULOQ were imputed at the ULOQ value. LLOQ= 159.79 and ULOQ= 11173.11. GMT of serum nAb against SARS-CoV-2 was measured by assay specific to wild-type virus.

    Time frame: At Days 29, 43, 57, 209, and 394

  9. GMFR of Serum nAb Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394

    The GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention. GMFR of serum nAb against SARS-CoV-2 was measured by assay specific to wild-type virus.

    Time frame: At Days 29, 43, 57, 209, and 394

  10. SCR of Serum nAb Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394

    SCR was defined at percentage of participants with a change from below the LOD or LLOQ to equal to or above LLOQ, OR, \>=4-fold rises from baseline. LLOQ= 159.79 and ULOQ= 11173.11. Baseline was defined as the last measurement taken before the first dose of study intervention. SCR of serum nAb against SARS-CoV-2 was measured by assay specific to wild-type virus.

    Time frame: At Days 29, 43, 57, 209, and 394

07

Results

Posted May 3, 2023

Participant flow

Participants took part in the study at 2 investigative sites in Japan from 07 January 2021 to 22 February 2022.

Participant flow — Overall Study
MilestonePlaceboTAK-919 0.5 mL
Started50150
Completed7137
Not completed4313
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject01
Withdrew: Chose publicly available vaccine4310

Outcome measures

PrimaryPercentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination

Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited local AEs included injection site pain, erythema/redness, swelling, induration, and axillary (underarm) swelling or tenderness ipsilateral to the side of injection.

Time frame:
Up to Day 7 (6 subsequent days after first vaccination on Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination
percentage of participantsPlaceboTAK-919 0.5 mL
Injection Site Pain6.082.7
Erythema/ Redness0.02.0
Swelling0.010.7
Induration0.06.0
Lymphadenopathy (Axillary Swelling or Tenderness at Same Side of Injection Site)4.011.3
PrimaryPercentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination

Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited local AEs included injection site pain, erythema/redness, swelling, induration, and axillary (underarm) swelling or tenderness ipsilateral to the side of injection.

Time frame:
Up to Day 35 (6 subsequent days after second vaccination on Day 29)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination
percentage of participantsPlaceboTAK-919 0.5 mL
Injection Site Pain2.085.0
Erythema/ Redness0.017.7
Swelling0.016.3
Induration0.012.9
Lymphadenopathy (Axillary Swelling or Tenderness at Same Side of Injection Site)6.010.2
PrimaryPercentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination

Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited systemic AEs included headache, fatigue, myalgia, arthralgia, nausea/ vomiting, chills, fever.

Time frame:
Up to Day 7 (6 subsequent days after first vaccination on Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination
percentage of participantsPlaceboTAK-919 0.5 mL
Headache0.013.3
Fatigue10.018.7
Myalgia4.037.3
Arthralgia0.08.0
Nausea/ Vomiting0.00.7
Chills2.05.3
Fever2.02.0
PrimaryPercentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination

Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited systemic AEs included headache, fatigue, myalgia, arthralgia, nausea/ vomiting, chills, fever.

Time frame:
Up to Day 35 (6 subsequent days after second vaccination on Day 29)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination
percentage of participantsPlaceboTAK-919 0.5 mL
Headache10.047.6
Fatigue8.063.3
Myalgia10.049.7
Arthralgia0.032.0
Nausea/ Vomiting0.04.1
Chills0.050.3
Fever0.040.1
PrimaryPercentage of Participants With Unsolicited AEs for 28 Days Following First Vaccination

Unsolicited AEs were all AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary.

Time frame:
Up to Day 29 (28 days after first vaccination on Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Unsolicited AEs for 28 Days Following First Vaccination
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With Unsolicited AEs for 28 Days Following First Vaccination18.020.7
PrimaryPercentage of Participants With Unsolicited AEs for 28 Days Following Second Vaccination

Unsolicited AEs were all AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary.

Time frame:
Up to Day 57 (28 days after second vaccination on Day 29)
Reported as:
Number · percentage of participants
Percentage of Participants With Unsolicited AEs for 28 Days Following Second Vaccination
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With Unsolicited AEs for 28 Days Following Second Vaccination14.019.0
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Until Day 57

Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this outcome measure (OM) and solicited SAE was out of the scope of the assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs until Day 57 was reported in this outcome measure.

Time frame:
Day 1 up to Day 57
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Until Day 57
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With Serious Adverse Events (SAEs) Until Day 570.00.0
PrimaryPercentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 57

MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAEs was out of the scope of the assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs until Day 57 was reported in this outcome measure.

Time frame:
Day 1 up to Day 57
Reported as:
Number · percentage of participants
Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 57
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 572.05.3
PrimaryPercentage of Participants With Any AE Leading to Discontinuation of Vaccination

Only unsolicited AE leading to discontinuation of vaccination data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to discontinuation of vaccination was out of the scope of the assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to discontinuation of vaccination was reported in this outcome measure.

Time frame:
Day 1 up to Day 57
Reported as:
Number · percentage of participants
Percentage of Participants With Any AE Leading to Discontinuation of Vaccination
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With Any AE Leading to Discontinuation of Vaccination0.01.3
PrimaryPercentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 57

Only unsolicited AE leading to participant's withdrawal data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal was out of the scope of the assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to participant's withdrawal from the trial until Day 57 was reported in this outcome measure.

Time frame:
Day 1 up to Day 57
Reported as:
Number · percentage of participants
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 57
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 570.00.0
PrimaryPercentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 57
Time frame:
Day 1 up to Day 57
Reported as:
Number · percentage of participants
Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 57
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 570.00.0
PrimaryGeometric Mean Titers (GMT) of Serum Binding Antibody (bAb) Against SARS-CoV-2 on Day 57

GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values measured as below lower limit of quantification (LLOQ) were imputed to a value that is half of the LLOQ. Titer values measured as above upper limit of quantification (ULOQ) were imputed at the ULOQ value. LLOQ=1 and ULOQ= 2052. GMT of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 spike (S) protein.

Time frame:
At Day 57
Reported as:
Geometric mean · arbitrary unit per milliliter (AU/mL)
Geometric Mean Titers (GMT) of Serum Binding Antibody (bAb) Against SARS-CoV-2 on Day 57
arbitrary unit per milliliter (AU/mL)PlaceboTAK-919 0.5 mL
Geometric Mean Titers (GMT) of Serum Binding Antibody (bAb) Against SARS-CoV-2 on Day 570.60 (0.53 to 0.67)813.05 (759.31 to 870.60)
PrimaryGeometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57

The GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention. GMFR of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

Time frame:
At Day 57
Reported as:
Geometric mean · fold change
Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 57
fold changePlaceboTAK-919 0.5 mL
Geometric Mean Fold Rise (GMFR) of Serum bAb Against SARS-CoV-2 on Day 570.90 (0.83 to 0.99)1009.25 (865.11 to 1177.40)
PrimarySeroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57

SCR was defined as percentage of participants with a change from below limit of detection (LOD) or LLOQ to equal to or above LOD or LLOQ, OR, greater than or equal to (\>=) 4-fold rises from baseline. LLOQ= 1, ULOQ= 2052. Baseline was defined as the last measurement taken before the first dose of study intervention. SCR of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

Time frame:
At Day 57
Reported as:
Number · percentage of participants
Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 57
percentage of participantsPlaceboTAK-919 0.5 mL
Seroconversion Rate (SCR) of Serum bAb Against SARS-CoV-2 on Day 572.0 (0.1 to 10.6)100.0 (97.5 to 100.0)
SecondaryPercentage of Participants With SAE Throughout the Trial

Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this OM and solicited SAE was out of the scope of the assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs throughout the trial was reported in this outcome measure.

Time frame:
Day 1 up to Day 394
Reported as:
Number · percentage of participants
Percentage of Participants With SAE Throughout the Trial
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With SAE Throughout the Trial0.00.0
SecondaryPercentage of Participants With MAAEs Throughout the Trial

MAAEs were defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAEs was out of the scope of the assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs throughout the trial was reported in this outcome measure.

Time frame:
Day 1 up to Day 394
Reported as:
Number · percentage of participants
Percentage of Participants With MAAEs Throughout the Trial
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With MAAEs Throughout the Trial4.014.7
SecondaryPercentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial

Only unsolicited AE leading to participant's withdrawal data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal was out of the scope of the assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant is not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to participant's withdrawal from the trial from the day of vaccination throughout the trial was reported in this outcome measure.

Time frame:
Day 1 up to Day 394
Reported as:
Number · percentage of participants
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial0.00.0
SecondaryPercentage of Participants With SARS-CoV-2 Infection Throughout the Trial
Time frame:
Day 1 up to Day 394
Reported as:
Number · percentage of participants
Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial
percentage of participantsPlaceboTAK-919 0.5 mL
Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial0.01.3
SecondaryGMT of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394

GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values measured as below LLOQ were imputed to a value that is half of the LLOQ. Titer values measured as above ULOQ were imputed at the ULOQ value. LLOQ=1 and ULOQ= 2052 until Day 43; LLOQ= 1 and ULOQ= 20520 from Day 209 and later. GMT of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

Time frame:
At Days 29, 43, 209 and 394
Reported as:
Geometric mean · AU/mL
GMT of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394
AU/mLPlaceboTAK-919 0.5 mL
Day 290.65 (0.57 to 0.74)140.72 (124.84 to 158.62)
Day 430.62 (0.55 to 0.70)1021.71 (940.66 to 1109.73)
Day 2090.70 (0.51 to 0.96)116.97 (106.26 to 128.76)
Day 3941.28 (0.38 to 4.33)53.36 (46.74 to 60.92)
SecondaryGMFR of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394

The GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention. GMFR of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

Time frame:
At Days 29, 43, 209 and 394
Reported as:
Geometric mean · fold change
GMFR of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394
fold changePlaceboTAK-919 0.5 mL
Day 290.99 (0.90 to 1.08)174.67 (148.72 to 205.16)
Day 430.93 (0.87 to 1.00)1268.26 (1073.44 to 1498.43)
Day 2091.00 (0.81 to 1.24)145.97 (124.69 to 170.89)
Day 3941.71 (0.44 to 6.63)65.01 (53.96 to 78.32)
SecondarySCR of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394

SCR was defined as percentage of participants with a change from below LOD or LLOQ to equal to or above LOD or LLOQ, OR \>=4-fold rises from baseline. LLOQ= 1 and ULOQ= 2052 until Day 43; LLOQ= 1 and ULOQ= 20520 from Day 209 and later. Baseline was defined as the last measurement taken before the first dose of study intervention. SCR of serum bAb against SARS-CoV-2 was measured by ligand-binding assay specific to the SARS-CoV-2 S protein.

Time frame:
At Days 29, 43, 209 and 394
Reported as:
Number · percentage of participants
SCR of Serum bAb Against SARS-CoV-2 on Days 29, 43, 209 and 394
percentage of participantsPlaceboTAK-919 0.5 mL
Day 296.0 (1.3 to 16.5)100.0 (97.5 to 100.0)
Day 432.0 (0.1 to 10.6)100.0 (97.5 to 100.0)
Day 2098.3 (0.2 to 38.5)99.3 (96.2 to 100.0)
Day 39428.6 (3.7 to 71.0)97.0 (92.5 to 99.2)
SecondaryGMT of Serum Neutralizing Antibody (nAb) Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394

GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values measured as below LLOQ were imputed to a value that is half of the LLOQ. Titer values measured as above ULOQ were imputed at the ULOQ value. LLOQ= 159.79 and ULOQ= 11173.11. GMT of serum nAb against SARS-CoV-2 was measured by assay specific to wild-type virus.

Time frame:
At Days 29, 43, 57, 209, and 394
Reported as:
Geometric mean · microneutralization titers (MN50)
GMT of Serum Neutralizing Antibody (nAb) Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394
microneutralization titers (MN50)PlaceboTAK-919 0.5 mL
Day 2979.9 (79.9 to 79.9)202.4 (170.5 to 240.2)
Day 4379.9 (79.9 to 79.9)5977.3 (5456.5 to 6547.9)
Day 5779.9 (79.9 to 79.9)1734.7 (1582.8 to 1901.2)
Day 20979.9 (79.9 to 79.9)741.3 (630.2 to 872.0)
Day 39479.9 (79.9 to 79.9)248.0 (202.8 to 303.2)
SecondaryGMFR of Serum nAb Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394

The GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention. GMFR of serum nAb against SARS-CoV-2 was measured by assay specific to wild-type virus.

Time frame:
At Days 29, 43, 57, 209, and 394
Reported as:
Geometric mean · fold change
GMFR of Serum nAb Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394
fold changePlaceboTAK-919 0.5 mL
Day 291.0 (1.0 to 1.0)2.5 (2.1 to 3.0)
Day 431.0 (1.0 to 1.0)74.8 (68.3 to 82.0)
Day 571.0 (1.0 to 1.0)21.7 (19.8 to 23.8)
Day 2091.0 (1.0 to 1.0)9.3 (7.9 to 10.9)
Day 3941.0 (1.0 to 1.0)3.1 (2.5 to 3.8)
SecondarySCR of Serum nAb Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394

SCR was defined at percentage of participants with a change from below the LOD or LLOQ to equal to or above LLOQ, OR, \>=4-fold rises from baseline. LLOQ= 159.79 and ULOQ= 11173.11. Baseline was defined as the last measurement taken before the first dose of study intervention. SCR of serum nAb against SARS-CoV-2 was measured by assay specific to wild-type virus.

Time frame:
At Days 29, 43, 57, 209, and 394
Reported as:
Number · percentage of participants
SCR of Serum nAb Against SARS-CoV-2 on Days 29, 43, 57, 209, and 394
percentage of participantsPlaceboTAK-919 0.5 mL
Day 290.0 (0.0 to 7.1)56.1 (47.5 to 64.5)
Day 430.0 (0.0 to 7.1)100.0 (97.5 to 100.0)
Day 570.0 (0.0 to 7.1)100.0 (97.5 to 100.0)
Day 2090.0 (0.0 to 26.5)94.4 (89.3 to 97.6)
Day 3940.0 (0.0 to 41.0)68.2 (59.4 to 76.1)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) are AEs that started after the first vaccination on Day 1 up to 365 days after the second vaccination on Day 29 (Day 394). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/50 (0%)0/50 (0%)21/50 (42%)
TAK-919 0.5 mL0/150 (0%)1/150 (0.7%)144/150 (96%)
Most frequent serious events
Most frequent serious events
EventPlaceboTAK-919 0.5 mL
OsteoarthritisMusculoskeletal and connective tissue disorders0/501/150
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboTAK-919 0.5 mL
Injection site painGeneral disorders4/50138/150
FatigueGeneral disorders9/5097/150
MyalgiaMusculoskeletal and connective tissue disorders7/5091/150
ChillsGeneral disorders1/5077/150
HeadacheNervous system disorders7/5074/150
Body temperature increasedInvestigations1/5060/150
ArthralgiaMusculoskeletal and connective tissue disorders1/5050/150
SwellingGeneral disorders0/5029/150
Vaccination site lymphadenopathyGeneral disorders4/5029/150
Vaccination site erythemaGeneral disorders0/5028/150

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of the treatment.

Age, Continuous
Age, Continuous(years)PlaceboTAK-919 0.5 mLTotal
Mean52.4 ± 14.1853.3 ± 15.6753.1 ± 15.28
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTAK-919 0.5 mLTotal
Female236588
Male2785112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTAK-919 0.5 mLTotal
Japanese50150200
Region of Enrollment
Region of Enrollment(Participants)PlaceboTAK-919 0.5 mLTotal
Japan50150200
Weight
Weight(kilogram (kg))PlaceboTAK-919 0.5 mLTotal
Mean62.49 ± 10.87061.05 ± 9.91861.41 ± 10.156
Height
Height(centimeter (cm))PlaceboTAK-919 0.5 mLTotal
Mean163.09 ± 8.501164.83 ± 8.549164.39 ± 8.549
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))PlaceboTAK-919 0.5 mLTotal
Mean23.35 ± 2.59522.39 ± 2.65322.63 ± 2.665
08

Study locations

2 sites
  • Sumida Hospital
    Sumida-ku, Tokyo, Japan
  • PS Clinic
    Fukuoka, Japan
09

References and documents

Publications

  • Masuda T, Murakami K, Sugiura K, Sakui S, Philip Schuring R, Mori M. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report. Vaccine. 2022 Mar 18;40(13):2044-2052. doi: 10.1016/j.vaccine.2022.02.030. Epub 2022 Feb 8. PubMed 35177302 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Feb 2022, 13 months.

Results were first posted in May 2023, 1 year 2 months after primary completion.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 13 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2020
First posted
Dec 21, 2020
StartActual
Jan 7, 2021
Primary completionActual
Feb 22, 2022
CompletionActual
Feb 22, 2022
Results first posted
May 3, 2023
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04677660
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Jan 7, 2021
Primary completion
Feb 22, 2022
Completion
Feb 22, 2022
Results posted
May 3, 2023
Last update
May 3, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273

Start the discussion